scholarly journals All-trans retinoic acid enhances temozolomide-induced autophagy in human glioma cells U251 via targeting Keap1/Nrf2/ARE signaling pathway

2017 ◽  
Vol 14 (3) ◽  
pp. 2709-2714 ◽  
Author(s):  
Lin Shi ◽  
Hongyuan Li ◽  
Yang Zhan
2011 ◽  
Vol 8 (1) ◽  
Author(s):  
Qing-xi Liu ◽  
Nan Wang ◽  
Xing-hua Liao ◽  
Guang-da Ren ◽  
Tao Qin ◽  
...  

2015 ◽  
Vol 148 (4) ◽  
pp. S-880 ◽  
Author(s):  
Shubha Priyamvada ◽  
Arivarasu Natarajan Anbazhagan ◽  
Anoop Kumar ◽  
Tarunmeet Gujral ◽  
Alip Borthakur ◽  
...  

2014 ◽  
Vol 79 ◽  
pp. 275-281 ◽  
Author(s):  
Chao Zhang ◽  
Xiaohong Kong ◽  
Guangzhi Ning ◽  
Zhipin Liang ◽  
Tongjun Qu ◽  
...  

2015 ◽  
Vol 10 (4) ◽  
pp. 966
Author(s):  
Ji-Heng Hao ◽  
Dian-Feng Hu ◽  
Li-Mei Mao ◽  
Shi-Gang Zhang ◽  
Ji-Yue Wang ◽  
...  

<p class="Abstract">The present study was performed to investigate the effect of 2-fluorobenzaldehyde retinoic acid conjugate on activation of STAT3 pathway in human glioma cells. The results revealed that the compound exhibited inhibitory effect on the activation of STAT3 induced constitutively and by interleukin-6. The inhibitory effect on STAT3 activation was found to be concentration- and time-dependent. In U373 glioma cells, 2-fluorobenzaldehyde retinoic acid conjugate treatment caused a significant enhancement in the expression of proapoptotic proteins like Bax and Bak. Its treatment inhibited the expression of genes including, cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1, and vascular endothelial growth factor (VEGF) in U373 glioma cells. Furthermore, the conjugate inhibited proliferation, induced apoptosis and caused accumulation of cells in G1-G0 phase of cell cycle. Thus, 2-fluorobenzaldehyde retinoic acid conjugate acts as a potent inhibitor of STAT3 activation that can be promising importance for the prevention and treatment of gliomas.</p><p> </p>


2013 ◽  
Vol 29 (6) ◽  
pp. 2269-2274 ◽  
Author(s):  
JIANRONG LU ◽  
FENG ZHANG ◽  
YONG YUAN ◽  
CAIXIA DING ◽  
LIYING ZHANG ◽  
...  

2020 ◽  
Author(s):  
Lungang Shi ◽  
Yan Liang ◽  
Lijing Yang ◽  
Binchen Li ◽  
Binna Zhang ◽  
...  

AbstractBackgroundAll-trans retinoic acid (atRA) results in cleft palate, but the cellular and molecular mechanisms underlying the teratogenic effects on palatal development have not been fully elucidated. Autophagy interruption has been reported to seriously affect embryonic-cell differentiation and development. This study aimed to verify whether atRA-induced cleft palate occurs because atRA blocks autophagy and stemness of embryonic palatal mesenchyme (MEPM) cells, which are maintained via the phosphatase and tensin homolog (PTEN)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) autophagic signaling pathway, and inhibits osteogenic-differentiation potential of MEPM cells, which could lead to the development of cleft palate.MethodsTo assess the stemness and pluripotency of MEPM cells, we analyzed their surfacemarkers using immunofluorescence (IF) and flow cytometry (FCM). Differentiation potentials, such as osteogenic, adipogenic, and chondrogenic differentiation, were induced. We also investigated the role of the PTEN/Akt/mTOR autophagic signaling pathway, which maintains the stemness and pluripotency of MEPM cells. Using transmission electron microscopy (TEM), Western blot analysis, quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), messenger ribonucleic acid (mRNA) microarray, dual-luciferase reporter system, and exosomes, we found that atRA blocks autophagy and osteogenic differentiation of MEPM cells through micro-ribonucleic acid (miR)-106a-5p by targeting the PTEN/Akt/mTOR autophagic pathway.ResultsIn vitro purified MEPM cells expressed cell surface markers similar to those of mouse bone marrow stem cells. Additionally, in vitro MEPM cells were ectomesenchymal and expressed the neural-crest marker human natural killer-1 (HNK-1), the mesodermal marker vimentin, and the ectodermal marker nestin. They were also positive for in vitro MEPM markers, including platelet-derived growth factor alpha (PDGFRα), ephrin B1 (Efnb1), odd-skipped related 2 (Osr2), and Meox2, as well as for stemness markers including POU class 5 homeobox 4 (Oct4), Nanog, and sex-determining region Y-related HMG box 2 (Sox2). MEPM cell pluripotency was retained through activation of the PTEN/Akt/mTOR autophagic signaling pathway. We found that atRA blocked MEPM cell pluripotency to inhibit osteogenic differentiation via miR-106a-5p targeting of PTEN mRNA and subsequent suppression of the PTEN/Akt/mTOR autophagic pathway.ConclusionsIn vitro cultured MEPM cells are ectomesenchymal stem cells that have strong osteogenic differentiation potential, and MEPM pluripotency is regulated by autophagy via the PTEN/AKT/mTOR signaling pathway. atRA disrupts MEPM cell pluripotency through PTEN/AKT/mTOR signaling inactivation where miR-106a-5p targets PTEN mRNA to reduce osteogenic differentiation of MEPM cells and results in the development of cleft palates. Our findings provide new insight into the mechanism underlying the development of cleft palate, and miR-106a-5p may act as a prenatal screening biomarker for cleft palate as well as a new diagnostic and therapeutic target.


Sign in / Sign up

Export Citation Format

Share Document